Published: 22 August 2019
Author(s): Baojian Liu, Ming Bai, Yan Wang, Di Wang, Jin Zhao, Lu Li, Ruijuan Dong, Shiren Sun
Issue: August 2019
Section: Original Article

The role of bortezomib in the treatment of immunoglobulin light chain (AL) amyloidosis is not well defined. We performed this meta-analysis to evaluate the efficacy and safety of bortezomib-based regimens in patients with AL amyloidosis who are not eligible for or refuse autologous stem cell transplantation.


Stay informed on our latest news!